Intelligent Bio Solutions Inc. (NASDAQ:INBS) shares traded 15.53% higher at $1.19 on Wall Street last session.
In accordance with the data, 1 analysts cover Intelligent Bio Solutions Inc. (NASDAQ:INBS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $1.60 and a low of $1.60, we find $1.60. Given the previous closing price of $1.03, this indicates a potential upside of 55.34 percent. INBS stock price is now 257.86% away from the 50-day moving average and 116.08% away from the 200-day moving average. The market capitalization of the company currently stands at $20.90M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $1.60 as their price target over the next twelve months.
Insiders disposed of 1,100,000 shares of company stock worth roughly $1.31 million over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in INBS stock. A new stake in Intelligent Bio Solutions Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $41,000. FMR LLC invested $12,000 in shares of INBS during the first quarter. In the first quarter, GOTHAM ASSET MANAGEMENT, LLC acquired a new stake in Intelligent Bio Solutions Inc. valued at approximately $12,000. In total, there are 13 active investors with 1.90% ownership of the company’s stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) opened at $1.2900 on Tuesday. During the past 12 months, Intelligent Bio Solutions Inc. has had a low of $0.17 and a high of $1.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for INBS is $0.3326 and a two-hundred day moving average price translates $0.5507 for the stock.
The latest earnings results from Intelligent Bio Solutions Inc. (NASDAQ: INBS) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.14, beating analysts’ expectations of -$0.18 by 0.04. This compares to -$0.10 EPS in the same period last year.
Intelligent Bio Solutions Inc.(INBS) Company Profile
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.